The UC Santa Barbara-launched food preservation technology developer’s latest round valued it at $2bn.
Matrix Capital Management led the immunology drug developer's series A round, which will support the journey of a type 1 diabetes drug candidate towards the clinic.
The no-code platform developer, spun out of MIT's Media Lab, will use the cash to boost international growth and accelerate the development of new product features.
The renewable energy battery developer, an MIT spinout, raised funding that will be used to expand its manufacturing capabilities.
University of Oxford’s genetic therapeutics spinout has secured the crossover funding eight months after a series A round also backed by OSI.
Osage University Partners has backed the immunotherapy developer in a series B round, which took its overall funding to over $335m.
A range of strategic investors have backed a series A5 round for the clean nuclear energy technology developer that leverages OSU research.
Intervenn Biosciences was co-founded by faculty members at Stanford University and University of California, Berkeley.
The MDC spinout raised a series B round which will be used to boost its manufacturing capacity and advance its pipeline of candidates.
University of Toronto-linked Deep Genomics has picked up $180m in its series C round led by SoftBank Vision Fund 2.